Literature DB >> 20844365

Ultrasound-based hepatic elastography: origins, limitations, and applications.

Eric B Cohen1, Nezam H Afdhal.   

Abstract

A reliable, noninvasive marker to help clinicians evaluate hepatic fibrosis is urgently needed. The liver biopsy, an imperfect gold standard, has recognized limitations including sampling error and interobserver variability. Hepatic elastography (HE) is a novel sonographic method for assessing liver stiffness and has excellent accuracy in making the diagnosis of minimal fibrosis and cirrhosis. Several conditions intrinsic to the pathology of the liver compromise the positive predictive value of HE for fibrosis alone including acute hepatitis, obstructive cholestasis, and passive congestion. Technical considerations that hinder the performance of elastography include an advanced body mass index, the presence of ascites and narrow intercostal spaces. Despite these limitations, elastography has a role in staging fibrosis, prognosis of disease outcome, surveillance, and treatment decisions. HE is now being used in lieu of liver biopsy to investigate the natural history of chronic liver diseases. Additional studies are required to better define the appropriate role of HE in clinical practice.

Entities:  

Mesh:

Year:  2010        PMID: 20844365     DOI: 10.1097/MCG.0b013e3181e12c39

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  12 in total

1.  Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions.

Authors:  Daniel L Motola; Peter Caravan; Raymond T Chung; Bryan C Fuchs
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

2.  Measuring fibrosis: is seeing really believing?

Authors:  Tuyet A T Nguyen; Richard K Sterling
Journal:  Dig Dis Sci       Date:  2012-08       Impact factor: 3.199

3.  Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection.

Authors:  Elliot B Tapper; Eric B Cohen; Keyur Patel; Bruce Bacon; Stuart Gordon; Eric Lawitz; David Nelson; Imad A Nasser; Tracy Challies; Nezam Afdhal
Journal:  Clin Gastroenterol Hepatol       Date:  2012-01-28       Impact factor: 11.382

4.  Fibroscan (transient elastography) for the measurement of liver fibrosis.

Authors:  Nezam H Afdhal
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-09

5.  Association of HIV, Hepatitis C Virus, and Liver Fibrosis Severity With the Enhanced Liver Fibrosis Score.

Authors:  Sophia Swanson; Yifei Ma; Rebecca Scherzer; Greg Huhn; Audrey L French; Michael W Plankey; Carl Grunfeld; William M Rosenberg; Marion G Peters; Phyllis C Tien
Journal:  J Infect Dis       Date:  2015-11-29       Impact factor: 5.226

6.  Association of HIV infection, hepatitis C virus infection, and metabolic factors with liver stiffness measured by transient elastography.

Authors:  M Rami Bailony; Rebecca Scherzer; Gregory Huhn; Michael W Plankey; Marion G Peters; Phyllis C Tien
Journal:  J Infect Dis       Date:  2013-07-30       Impact factor: 5.226

7.  Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models.

Authors:  Miloslav Polasek; Bryan C Fuchs; Ritika Uppal; Daniel T Schühle; Jamu K Alford; Galen S Loving; Suguru Yamada; Lan Wei; Gregory Y Lauwers; Alexander R Guimaraes; Kenneth K Tanabe; Peter Caravan
Journal:  J Hepatol       Date:  2012-05-24       Impact factor: 25.083

Review 8.  Non-alcoholic fatty liver disease in 2015.

Authors:  Monjur Ahmed
Journal:  World J Hepatol       Date:  2015-06-18

Review 9.  Review of MR elastography applications and recent developments.

Authors:  Kevin J Glaser; Armando Manduca; Richard L Ehman
Journal:  J Magn Reson Imaging       Date:  2012-10       Impact factor: 4.813

10.  Points to be considered when applying FibroScan S probe in children with biliary atresia.

Authors:  Seung Kim; Yunkoo Kang; Mi Jung Lee; Myung Joon Kim; Seok Joo Han; Hong Koh
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-11       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.